Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNZ-2591 in Phelan-McDermid Syndrome
NCT05025241Phase 2Completed
- Sponsor
- Neuren Pharmaceuticals Limited
- Start
- Aug 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NNZ-2591 in Phelan-McDermid syndrome (PMS), sponsored by Neuren Pharmaceuticals Limited. Primary endpoints: Safety and Tolerability at 13 weeks, Area Under the Curve over 24 hours and 1 more. Started Aug 2022; status: completed.
02
Drugs
NNZ-2591
03
Conditions
Phelan-McDermid syndrome (PMS)
Beyond the preview
Go deeper on NCT05025241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05025241.